|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table** S**1**: Standard deviation of normal-to-normal RR intervals (SDNN) recorded during use or non-use of antidepressants | | | | | | | | |
|  | Total cohort, model 1 | |  | Subsample, model 1 | |  | Subsample, model 2 | |
|  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |
| Non-use of antidepressants (ref) | 22,971 | 0 |  |  | 0 |  |  | 0 |
|  |  |  |  |  |  |  |  |  |
| TCA use | 296 | -0.16 (-0.24; -0.08) |  | 180 | -0.16 (-0.26; -0.05) |  | 180 | -0.16 (-0.26; -0.06) |
| - Imipramine | 16 | -0.13 (-0.47; 0.21) |  | 10 | -0.03 (-0.44; 0.38) |  | 10 | -0.04 (-0.44; 0.38) |
| - Clomipramine | 27 | -0.51 (-0.77; -0.24) |  | 16 | -0.51 (-0.85; -0.17) |  | 16 | -0.51 (-0.85; -0.17) |
| - Amitriptyline | 185 | -0.10 (-0.21; 0.00) |  | 121 | -0.08 (-0.20; 0.05) |  | 121 | -0.08 (-0.21; 0.05) |
| - Nortriptyline | 13 | -0.56 (-0.98; -0.16) |  | 11 | -0.63 (-1.06; -0.20) |  | 11 | -0.63 (-1.06; -0.2) |
| - Maprotiline | 48 | -0.15 (-0.36; 0.05) |  | 20 | -0.16 (-0.48; 0.16) |  | 20 | -0.16 (-0.48; 0.16) |
|  |  |  |  |  |  |  |  |  |
| SSRI use | 380 | -0.17 (-0.25; -0.10) |  | 318 | -0.16 (-0.24; -0.09) |  | 318 | -0.17 (-0.24; -0.09) |
| - Fluoxetine | 35 | -0.37 (-0.60; -0.15) |  | 22 | -0.43 (-0.70; -0.15) |  | 22 | -0.43 (-0.71; -0.15) |
| - Citalopram | 28 | -0.07 (-0.32; 0.17) |  | 25 | -0.11 (-0.36; 0.14) |  | 25 | -0.11 (-0.36; 0.14) |
| - Paroxetine | 237 | -0.18 (-0.27; -0.09) |  | 207 | -0.17 (-0.26; -0.07) |  | 207 | -0.17 (-0.26; -0.08) |
| - Sertraline | 37 | -0.14 (-0.37; 0.09) |  | 34 | -0.15 (-0.37; 0.08) |  | 34 | -0.15 (-0.38; 0.07) |
| - Fluvoxamine | 39 | -0.03 (-0.25; 0.19) |  | 26 | 0.12 (-0.14; 0.39) |  | 26 | 0.12 (-0.14; 0.38) |

Abbreviations: CI, confidence interval; ECGs, electrocardiograms; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. Results presented as betas and 95% confidence intervals of the log-transformed measure. The total cohort comprised all eligible electrocardiograms. The subsample cohort comprised of ECGs with data on depressive symptoms. Model 1: adjusted for age, sex, RR interval, use of beta-blockers, verapamil and diltiazem. Model 2: adjusted for age, sex, RR interval, use of beta-blockers, verapamil, diltiazem and depressive symptoms.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table** S**2**: Root mean square of successive differences (RMSSD) recorded during use non-use or of antidepressants | | | | | | | | |
|  | Total cohort | |  | Subsample cohort, model 1 | |  | Subsample cohort, model 2 | |
|  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |
| Non-use of antidepressants (ref) | 22,971 | 0 |  |  | 0 |  |  | 0 |
|  |  |  |  |  |  |  |  |  |
| TCA use | 296 | -0.17 (-0.25; -0.08) |  | 180 | -0.17 (-0.28; -0.07) |  | 180 | -0.18 (-0.28; -0.07) |
| - Imipramine | 16 | -0.02 (-0.36; 0.33) |  | 10 | -0.03 (-0.44; 0.37) |  | 10 | -0.04 (-0.45; 0.37) |
| - Clomipramine | 27 | -0.54 (-0.81; -0.28) |  | 16 | -0.61 (-0.95; -0.27) |  | 16 | -0.61 (-0.95; -0.27) |
| - Amitriptyline | 185 | -0.12 (-0.23; -0.02) |  | 121 | -0.10 (-0.22; 0.03) |  | 121 | -0.10 (-0.22; 0.03) |
| - Nortriptyline | 13 | -0.55 (-0.97; -0.14) |  | 11 | -0.58 (-1.02; -0.14) |  | 11 | -0.59 (-1.03; -0.15) |
| - Maprotiline | 48 | -0.14 (-0.35; 0.06) |  | 20 | -0.13 (-0.45; 0.20) |  | 20 | -0.13 (-0.45; 0.20) |
|  |  |  |  |  |  |  |  |  |
| SSRI use | 380 | -0.15 (-0.22; -0.08) |  | 318 | -0.14 (-0.22; -0.07) |  | 318 | -0.14 (-0.22; -0.07) |
| - Fluoxetine | 35 | -0.33 (-0.55; -0.10) |  | 22 | -0.42 (-0.69; -0.14) |  | 22 | -0.42 (-0.69; -0.15) |
| - Citalopram | 28 | -0.09 (-0.34; 0.16) |  | 25 | -0.13 (-0.37; 0.12) |  | 25 | -0.13 (-0.38; 0.11) |
| - Paroxetine | 237 | -0.15 (-0.24; -0.05) |  | 207 | -0.13 (-0.22; -0.04) |  | 207 | -0.13 (-0.23; -0.04) |
| - Sertraline | 37 | -0.15 (-0.38; 0.08) |  | 34 | -0.17 (-0.39; 0.05) |  | 34 | -0.18 (-0.40; 0.05) |
| - Fluvoxamine | 39 | 0.00 (-0.22; 0.22) |  | 26 | 0.09 (-0.17; 0.36) |  | 26 | 0.09 (-0.17; 0.35) |

Abbreviations: CI, confidence interval; ECGs, electrocardiograms; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. Results presented as betas and 95% confidence intervals of the log-transformed measure. The total cohort comprised all eligible electrocardiograms. The subsample cohort comprised of ECGs with data on depressive symptoms. Model 1: adjusted for age, sex, RR interval, use of beta-blockers, verapamil and diltiazem. Model 2: adjusted for age, sex, RR interval, use of beta-blockers, verapamil, diltiazem and depressive symptoms

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table** S**3**: RR interval recorded during use and non-use of antidepressants | | | | | | | | |
|  | Total cohort, model 1 | |  | Subsample, model 1 | |  | Subsample, model 2 | |
|  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |  | ECGs | Beta (95% CI) |
| Non-use of antidepressants (ref) | 22,971 | 0 |  |  | 0 |  |  | 0 |
|  |  |  |  |  |  |  |  |  |
| TCA use | 296 | -81.8 (96.0; -67.5) |  | 180 | -90.2 (109; -71.4) |  | 180 | -89.4 (-108; -70.6) |
| - Imipramine | 16 | -105 (-166; -43.9) |  | 10 | -108 (-189; -26.6) |  | 10 | -106 (-187; -24.5) |
| - Clomipramine | 27 | -47.6 (-91.3; -3.9) |  | 16 | -41 (-100; 17.5) |  | 16 | -42 (-101; 16.6) |
| - Amitriptyline | 185 | -82.6 (-100.9; -64.3) |  | 121 | -90.1 (-113; -67) |  | 121 | -89.4 (-112; -66) |
| - Nortriptyline | 13 | -143 (-207; -79) |  | 11 | -132 (-204; -59.3) |  | 11 | -130 (-202; -57) |
| - Maprotiline | 48 | -90.3 (-126; -55) |  | 20 | -106.6 (-167; -45.9) |  | 20 | -106 (-166; -45) |
|  |  |  |  |  |  |  |  |  |
| SSRI use | 380 | 14.1 (1.6; 26.6) |  | 318 | 14.4 (0.3; 28.5) |  | 318 | 15.5 (1.3; 29.7) |
| - Fluoxetine | 35 | 28.9 (-9.8; 67.7) |  | 22 | 37.6 (-15.0; 90.2) |  | 22 | 39 (-14; 91.5) |
| - Citalopram | 28 | 7.6 (-37.9; 53.2) |  | 25 | 0.6 (-48.1; 49.3) |  | 25 | 2.3 (-46.4; 51.0) |
| - Paroxetine | 237 | 5.8 (-9.9; 21.5) |  | 207 | 7.2 (-10.0; 24.5) |  | 207 | 8.0 (-9.3; 25.3) |
| - Sertraline | 37 | 47.8 (8.2; 87.5) |  | 34 | 39.4 (-1.8; 80.7) |  | 34 | 41.4 (0.2; 82.7) |
| - Fluvoxamine | 39 | 18.3 (-21.0; 57.6) |  | 26 | 32.8 (-19.6; 85.2) |  | 26 | 34.3 (-18.1; 86.7) |

Abbreviations: CI, confidence interval; ECGs, electrocardiograms; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. Results presented as betas and 95% confidence intervals of the log-transformed measure. The total cohort comprised all eligible electrocardiograms. The subsample cohort comprised ECGs with data on depressive symptoms. Model 1: adjusted for age, sex, use of beta-blockers, verapamil and diltiazem. Model 2: adjusted for age, sex, use of beta-blockers, verapamil, diltiazem and depressive symptoms.